- Home
- CVAC vs PEB Comparison
CVAC vs PEB Comparison
Compare CVAC & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVAC | PEB |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CVAC | PEB |
|---|---|---|
| Price | $5.17 | $10.96 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 9 |
| Target Price | $6.83 | ★ $12.28 |
| AVG Volume (30 Days) | 1.6M | ★ 2.0M |
| Earning Date | 11-24-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 0.36% |
| EPS Growth | ★ 94.02 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | $83,000,117.00 | ★ $1,464,126,000.00 |
| Revenue This Year | N/A | $2.25 |
| Revenue Next Year | $23.40 | $2.96 |
| P/E Ratio | $5.51 | ★ N/A |
| Revenue Growth | N/A | ★ 0.99 |
| 52 Week Low | $2.48 | $7.42 |
| 52 Week High | $5.72 | $15.12 |
Technical Indicators
Market Signals| Indicator | CVAC | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 49.19 |
| Support Level | $5.11 | $10.46 |
| Resistance Level | $5.55 | $11.58 |
| Average True Range (ATR) | 0.12 | 0.34 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 35.00 | 45.98 |
Price Performance
Historical ComparisonAbout CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.